Heart health after immunotherapy for melanoma
Part of Cancer, Heart & circulation, Injuries & trauma, Skin clinical trials.
This study looks at heart health in people who have finished immunotherapy for melanoma. It uses MRI scans to check for any heart problems that may have developed after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with melanoma.
- Your melanoma was at stage IIB, IIC, III, or IV.
- You have finished immunotherapy (a type of cancer treatment that helps your immune system fight cancer) and are now on regular check-ups.
- It has been between 2 and over 10 years since you finished immunotherapy.
- You are 18 years or older.
- You do not have any metal implants (like some pacemakers or clips) that are not safe for MRI scans, and you are not claustrophobic or pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a simple blood test (liquid biopsy) to track how well melanoma responds to immunotherapy. It might help doctors decide if treatment is working or needs to be changed.
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
This study looks at whether certain immunotherapy drugs (nivolumab, pembrolizumab, or ipilimumab) affect the heart in people with skin cancer. You will have special heart imaging to check for any early signs of heart problems.
This study tests whether giving aggressive cholesterol-lowering medication to people starting immunotherapy for melanoma can improve heart health. It may help reduce the risk of heart problems during cancer treatment.
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
This study looks for specific markers in the blood that can help doctors better understand and treat heart inflammation (myocarditis) caused by immunotherapy in people with lung cancer. If you join, you will help find ways to improve care for other patients.
Hear when a new Melanoma Stage III or IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.